AHK-Cu significantly stimulates vascular endothelial growth factor (VEGF), a key driver of angiogenesis, or the formation of new capillaries that deliver oxygen and nutrients to dermal tissue
What Could Speed Up Approval Rolling BLA Submission: Submitting sections as data became available rather than waiting for all four trials this is no longer a live possibility since all trials are already complete, but it's part of why Q1 2027 (rather than later) remains achievable
If continued treatment is financially unsustainable, planned discontinuation with the protocol above is preferable to abrupt cessation due to inability to refill
Mechanistically, sorafenib suppresses system Xc-, which promotes ER stress, GSH depletion, and the iron-dependent accumulation of lipid ROS (Sun et al., 2016b)
95% confidence intervals are reported throughout